- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Articles from ACR Convergence 2020
Here are the top 5 biosimilar articles from the American College of Rheumatology (ACR) Convergence 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
The American College of Rheumatology’s (ACR) Convergence 2020 was the annual meeting of the ACR. This year, due to the pandemic, the meeting was hosted virtually from November 5 to 9. During the conference, a number of study findings were presented on biosimilars used to treat rheumatic diseases. Here are the top 5 biosimilar articles from ACR Convergence 2020.
Number 5: One study of multiple biosimilar switches for patients with a variety of rheumatic musculoskeletal diseases demonstrated a high rate of patient retention and no major changes in disease activity or function.
Number 4: In a study of the use of infliximab biosimilars among patients with gastrointestinal and rheumatologic conditions, investigators found high adherence.
Number 3: Investigators presented evidence of what they say are successful, first-time tests of a multibiomarker disease activity score in patients with rheumatoid arthritis.
Number 2: Separate studies, including one on application methods for Celltrion’s adalimumab biosimilar candidate (CT-P17), were reported at the ACR Convergence 2020.
Number 1: Poster presentations at the meeting shed light on performance of Pfizer’s and Celltrion’s versions of adalimumab biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD
April 3rd 2025The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.
